Acquisition Premium89bio announced that it has entered into a merger agreement to be acquired by Roche at a price of $14.50 per share in cash at closing, representing a premium of approximately 79% to ETNB's closing stock price on September 17.
Market PotentialHigh conviction in the MASH space as a large and growing market with the FGF21 class being one of the most potent anti-fibrotic mechanisms in development.
Strategic FitThis transaction reflects pegozafermin's potential best-in-disease profile for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis and highlights its strategic fit within Roche's cardiovascular, renal, and metabolism portfolio.